Arch Biopartners (TSXV:ARCH) Common Stock : C$15.88 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Common Stock?

Arch Biopartners's quarterly common stock stayed the same from Jun. 2023 (C$15.88 Mil) to Sep. 2023 (C$15.88 Mil) and stayed the same from Sep. 2023 (C$15.88 Mil) to Dec. 2023 (C$15.88 Mil).

Arch Biopartners's annual common stock increased from Sep. 2021 (C$14.76 Mil) to Sep. 2022 (C$15.55 Mil) and increased from Sep. 2022 (C$15.55 Mil) to Sep. 2023 (C$15.88 Mil).

Arch Biopartners Common Stock Historical Data

The historical data trend for Arch Biopartners's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Common Stock Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Common Stock

Get a 7-Day Free Trial

12.03

13.71

14.76

15.55

15.88

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															15.76	15.76	15.88	15.88	15.88

Arch Biopartners Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.